Can Legal Cannabis Access Reduce Misuse and Improve Mental Health?

As more regions move toward cannabis legalization, one critical question lingers: Does legal access actually help users reduce problematic use and improve mental health?  A recent randomized controlled trial¹ out of Switzerland looked to answer this, with findings that may change how detractors of the plant view its medicinal value.

Public Health or Prohibition: Testing the Real-World Impact

Conducted in Basel-Stadt, Switzerland, this 6-month trial was the first of its kind to assign adult cannabis users to one of two groups randomly:

• Legal Access Group: Participants could buy regulated cannabis through local pharmacies, complete with dosage labeling, harm-reduction info, and access to optional counseling.
• Control Group: Continued sourcing cannabis through the illegal market.

In total, 374 adults were enrolled, all of whom were existing cannabis users.  The study was built on a public health framework without the use of flashy marketing or high-potency gimmicks, just clean cannabis and informed support.

Key Finding: Legal Access May Curb Problematic Use

The headline result?  A modest yet meaningful drop in cannabis misuse was observed in the legal access group.

Using the Cannabis Use Disorders Identification Test – Revised (CUDIT-R), the legal group showed a decline in misuse scores from 10.9 to 10.1 over six months.  While the change just missed conventional statistical significance (P = 0.052), it suggests a trend worth watching.

Most notably, the reduction was especially significant among participants who also used other drugs.  For this subgroup, the drop in problematic cannabis use was nearly 2 points greater than those not using other substances – a change considered “clinically reliable.”

What Did Not Change? Mental Health, Alcohol, and Other Use

While the study hinted at reduced cannabis misuse, it found no significant differences in depression, anxiety, psychosis symptoms, or alcohol/drug use between the groups.

This aligns with prior research from countries like Canada and the U.S., where legalization has shown little effect, positive or negative, on mental health outcomes at the population level.  It also reinforces the importance of setting realistic expectations: legalization alone is not a mental health solution, but it does not seem to worsen outcomes either.

Why This Study Matters

Most past research relied on observational data, comparing states or countries before and after legalization.  This randomized and controlled trial offers a more trustworthy causal link between legal access and user behavior. Moreover, the study design prioritized harm reduction:

• Quality-controlled, contaminant-free cannabis
• THC-limited products (max 20%)
• Voluntary counseling options
• Clear dosage labels and safety info

In short, it tested not just legal cannabis, but responsibly regulated cannabis – a key distinction.

Cannabis, Recovery, and Happiness: A Bigger Picture

Beyond misuse scores, emerging research is highlighting cannabis’s evolving role in recovery.  According to one report, medical cannabis has helped individuals reduce cravings for harder substances such as opioids and stimulants, while also improving treatment retention rates.

Another study explored cannabis use through the lens of happiness and well-being.  It found that some individuals in recovery report greater life satisfaction and reduced stress when cannabis is used responsibly and legally, supporting the idea that context, access, and regulation matter as much as the substance itself.

These insights complement the Swiss trial’s findings: a tightly regulated, public health-based cannabis model may support not only safer use but also personal wellbeing, particularly when it includes education, harm reduction tools, and access to alternative supports.

Final Thoughts

This was only the first six months of the study.  A two-year observational follow-up is in progress and will provide deeper insights into long-term effects, including whether these early trends hold or strengthen over time.  For now, though, it has given weight to the idea that a public health-focused cannabis policy can reduce harm, particularly for those at greater risk of substance misuse.  It also highlights some limitations:

• Nearly half of the legal access group still used illegal cannabis, often citing convenience, price, or dissatisfaction with legal products.
• The trial excluded individuals with acute psychiatric conditions, so findings may not apply to high-risk populations.

Still, for mainstream adult users, legalization paired with support services appears to do more good than harm.

In a world where cannabis policy is evolving rapidly, Switzerland’s approach offers a valuable roadmap.  Legal access, when done right, may not only avoid increasing harm — it could actively support better outcomes for some users.

Studies Referenced:

^{1. Baltes-Flueckiger L, Steinauer R, Meyer M, Guessoum A, Herrmann O, Mosandl CF, et al. Effects of legal access versus illegal market cannabis on use and mental health: A randomized controlled trial. Addiction. 2025. https://doi.org/10.1111/add.70080}